SEC Comment Letter 0000000000-22-012264 to Annexon, Inc. (ANNX) (CIK 0001528115) (ANNX)
Annexon, Inc. (ANNX) (CIK 0001528115)
Date: Nov. 10, 2022 · CIK: 0001528115 · Accession: 0000000000-22-012264
AI Filing Summary & Sentiment
File numbers found in text: 333-268181
Letter
United States securities and exchange commission logo November 10, 2022 Douglas Love Chief Executive Officer Annexon, Inc. 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, CA 94005 Re:Annexon, Inc. Registration Statement on Form S-3 Filed November 4, 2022 File No. 333-268181 Dear Douglas Love: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kathleen M. Wells, Esq.
Show Raw Text
United States securities and exchange commission logo
November 10, 2022
Douglas Love
Chief Executive Officer
Annexon, Inc.
1400 Sierra Point Parkway, Bldg C, Suite 200
Brisbane, CA 94005
Re:Annexon, Inc.
Registration Statement on Form S-3
Filed November 4, 2022
File No. 333-268181
Dear Douglas Love:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Kathleen M. Wells, Esq.